Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
This article was originally published in The Gray Sheet
Executive Summary
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
You may also be interested in...
Guidant Contak CD CHF Data Mixed But Show Significant Functional Gains
Guidant's Contak CD implantable pulse generator significantly improves the functional capacity of patients with congestive heart failure, as evidenced by peak oxygen consumption, although other benefits demonstrated in a 581-patient study did not reach the level of statistical significance, the company says.
Guidant Contak CD CHF Data Mixed But Show Significant Functional Gains
Guidant's Contak CD implantable pulse generator significantly improves the functional capacity of patients with congestive heart failure, as evidenced by peak oxygen consumption, although other benefits demonstrated in a 581-patient study did not reach the level of statistical significance, the company says.
Guidant Looking For Contak To Regain ICD Market Share Lost To Medtronic
Guidant's eroding share in the implantable cardioverter defibrillator market during the first quarter of 2001 can be attributed to increased off-label use of competitor Medtronic's Gem III dual-chamber ICD device to treat patients with congestive heart failure, Guidant officials explained during an earnings teleconference.